Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Escherichia coli and Staphylococcus aureus: leading bacterial pathogens of healthcare associated infections and bacteremia in older-age populations.

Poolman JT, Anderson AS.

Expert Rev Vaccines. 2018 Jul;17(7):607-618. doi: 10.1080/14760584.2018.1488590. Epub 2018 Jul 9. Review.

PMID:
29902092
2.

Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine.

Abbanat D, Davies TA, Amsler K, He W, Fae K, Janssen S, Poolman JT, van den Dobbelsteen GPJM.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00123-17. doi: 10.1128/CVI.00123-17. Print 2017 Dec.

3.

Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models.

van den Dobbelsteen GPJM, Faé KC, Serroyen J, van den Nieuwenhof IM, Braun M, Haeuptle MA, Sirena D, Schneider J, Alaimo C, Lipowsky G, Gambillara-Fonck V, Wacker M, Poolman JT.

Vaccine. 2016 Jul 29;34(35):4152-4160. doi: 10.1016/j.vaccine.2016.06.067. Epub 2016 Jul 6.

PMID:
27395567
4.

Predicting future trends in the burden of pertussis in the 21st century: implications for infant pertussis and the success of maternal immunization.

van den Biggelaar AH, Poolman JT.

Expert Rev Vaccines. 2016;15(1):69-80. doi: 10.1586/14760584.2016.1105136. Epub 2015 Nov 11. Review.

PMID:
26559122
5.

Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field.

Poolman JT, Wacker M.

J Infect Dis. 2016 Jan 1;213(1):6-13. doi: 10.1093/infdis/jiv429. Epub 2015 Sep 2. Review.

6.

Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness.

Poolman JT, Richmond P.

Expert Rev Vaccines. 2015;14(9):1277-87. doi: 10.1586/14760584.2015.1071670. Epub 2015 Jul 23. Review.

PMID:
26204792
7.

Foreword. Pertussis vaccines.

Poolman JT.

Expert Rev Vaccines. 2014 Sep;13(9):1067-9. doi: 10.1586/14760584.2014.946910. No abstract available.

PMID:
25115214
8.

Shortcomings of pertussis vaccines: why we need a third generation vaccine.

Poolman JT.

Expert Rev Vaccines. 2014 Oct;13(10):1159-62. doi: 10.1586/14760584.2014.944902. Epub 2014 Aug 4.

PMID:
25089373
9.

Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.

Pauksens K, Nilsson AC, Caubet M, Pascal TG, Van Belle P, Poolman JT, Vandepapelière PG, Verlant V, Vink PE.

Clin Vaccine Immunol. 2014 May;21(5):651-60. doi: 10.1128/CVI.00807-13. Epub 2014 Mar 5.

10.

Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.

Williams JN, Weynants V, Poolman JT, Heckels JE, Christodoulides M.

Vaccine. 2014 Mar 5;32(11):1280-6. doi: 10.1016/j.vaccine.2013.12.070. Epub 2014 Jan 30.

PMID:
24486354
11.

Zinc piracy as a mechanism of Neisseria meningitidis for evasion of nutritional immunity.

Stork M, Grijpstra J, Bos MP, Mañas Torres C, Devos N, Poolman JT, Chazin WJ, Tommassen J.

PLoS Pathog. 2013 Oct;9(10):e1003733. doi: 10.1371/journal.ppat.1003733. Epub 2013 Oct 31.

12.

The history of pneumococcal conjugate vaccine development: dose selection.

Poolman JT, Peeters CC, van den Dobbelsteen GP.

Expert Rev Vaccines. 2013 Dec;12(12):1379-94. doi: 10.1586/14760584.2013.852475. Review.

PMID:
24195479
13.

Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.

Leroux-Roels I, Devaster JM, Leroux-Roels G, Verlant V, Henckaerts I, Moris P, Hermand P, Van Belle P, Poolman JT, Vandepapelière P, Horsmans Y.

Vaccine. 2015 Jan 15;33(4):577-84. doi: 10.1016/j.vaccine.2013.10.052. Epub 2013 Oct 29.

14.

Evaluation of truncated NhhA protein as a candidate meningococcal vaccine antigen.

Peak IR, Srikhanta YN, Weynants VE, Feron C, Poolman JT, Jennings MP.

PLoS One. 2013 Sep 6;8(9):e72003. doi: 10.1371/journal.pone.0072003. eCollection 2013.

15.

Description and nomenclature of Neisseria meningitidis capsule locus.

Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, Frasch CE, Stephens DS, Feavers I, Frosch M, Parkhill J, Vogel U, Quail MA, Bentley SD, Maiden MC.

Emerg Infect Dis. 2013 Apr;19(4):566-73. doi: 10.3201/eid1904.111799.

16.

ZnuD, a potential candidate for a simple and universal Neisseria meningitidis vaccine.

Hubert K, Devos N, Mordhorst I, Tans C, Baudoux G, Feron C, Goraj K, Tommassen J, Vogel U, Poolman JT, Weynants V.

Infect Immun. 2013 Jun;81(6):1915-27. doi: 10.1128/IAI.01312-12. Epub 2013 Mar 18.

17.

Neisseria meningitidis serogroup B lipooligosaccharide genotyping reveals high prevalence of L2 strains in Spain and unexpected relationship with factor H-binding protein expression.

Devos N, Tans C, Momin P, Plisnier M, Weynants V, Feron C, Poolman JT.

Microbes Infect. 2012 Sep;14(11):979-88. doi: 10.1016/j.micinf.2012.04.005. Epub 2012 Apr 20.

PMID:
22565133
18.

Meningococcal surface fibril (Msf) binds to activated vitronectin and inhibits the terminal complement pathway to increase serum resistance.

Griffiths NJ, Hill DJ, Borodina E, Sessions RB, Devos NI, Feron CM, Poolman JT, Virji M.

Mol Microbiol. 2011 Dec;82(5):1129-49. doi: 10.1111/j.1365-2958.2011.07876.x. Epub 2011 Nov 4.

19.

Pertussis vaccines: where to now?

Poolman JT, Hallander H, Halperin SA.

Expert Rev Vaccines. 2011 Nov;10(11):1497-500. doi: 10.1586/erv.11.147. No abstract available.

PMID:
22043947
20.

A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.

Denoël P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT.

Vaccine. 2011 Jul 26;29(33):5495-501. doi: 10.1016/j.vaccine.2011.05.051. Epub 2011 May 30.

21.

Meningococcal serogroup B vaccines: will they live up to expectations?

Zollinger WD, Poolman JT, Maiden MC.

Expert Rev Vaccines. 2011 May;10(5):559-61. doi: 10.1586/erv.11.41. No abstract available.

22.

Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.

Poolman JT, De Vleeschauwer I, Durant N, Devos N, Feron C, Lestrate P, Weynants V, Boutriau D.

Clin Vaccine Immunol. 2011 Jul;18(7):1108-17. doi: 10.1128/CVI.00549-10. Epub 2011 May 18.

23.

Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.

Rose CE, Romero-Steiner S, Burton RL, Carlone GM, Goldblatt D, Nahm MH, Ashton L, Haston M, Ekström N, Haikala R, Käyhty H, Henckaerts I, Durant N, Poolman JT, Fernsten P, Yu X, Hu BT, Jansen KU, Blake M, Simonetti ER, Hermans PW, Plikaytis BD.

Clin Vaccine Immunol. 2011 Jan;18(1):135-42. doi: 10.1128/CVI.00370-10. Epub 2010 Nov 17.

24.

Transcriptional regulation, occurrence and putative role of the Pht family of Streptococcus pneumoniae.

Rioux S, Neyt C, Di Paolo E, Turpin L, Charland N, Labbé S, Mortier MC, Mitchell TJ, Feron C, Martin D, Poolman JT.

Microbiology. 2011 Feb;157(Pt 2):336-48. doi: 10.1099/mic.0.042184-0. Epub 2010 Oct 21.

PMID:
20966093
25.

Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.

Godfroid F, Hermand P, Verlant V, Denoël P, Poolman JT.

Infect Immun. 2011 Jan;79(1):238-45. doi: 10.1128/IAI.00378-10. Epub 2010 Oct 18.

26.

An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential.

Stork M, Bos MP, Jongerius I, de Kok N, Schilders I, Weynants VE, Poolman JT, Tommassen J.

PLoS Pathog. 2010 Jul 1;6:e1000969. doi: 10.1371/journal.ppat.1000969.

27.

Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.

Marshall GS, Marchant CD, Blatter M, Aris E, Boutriau D, Poolman JT, Friedland LR, Miller JM.

Pediatr Infect Dis J. 2010 May;29(5):469-71. doi: 10.1097/INF.0b013e3181cdd379.

PMID:
20072077
28.

Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I.

Clin Vaccine Immunol. 2010 Jan;17(1):134-42. doi: 10.1128/CVI.00289-09. Epub 2009 Nov 4.

29.

Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response.

Weynants V, Denoël P, Devos N, Janssens D, Feron C, Goraj K, Momin P, Monnom D, Tans C, Vandercammen A, Wauters F, Poolman JT.

Infect Immun. 2009 May;77(5):2084-93. doi: 10.1128/IAI.01108-08. Epub 2009 Mar 16.

30.

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007.

Tondella ML, Carlone GM, Messonnier N, Quinn CP, Meade BD, Burns DL, Cherry JD, Guiso N, Hewlett EL, Edwards KM, Xing D, Giammanco A, Wirsing von König CH, Han L, Hueston L, Robbins JB, Powell M, Mink CM, Poolman JT, Hildreth SW, Lynn F, Morris A.

Vaccine. 2009 Feb 5;27(6):803-14. doi: 10.1016/j.vaccine.2008.11.072. Epub 2008 Dec 9.

PMID:
19071179
31.

Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates.

Dagan R, Poolman JT, Zepp F.

Expert Rev Vaccines. 2008 Feb;7(1):97-115. doi: 10.1586/14760584.7.1.97. Review.

PMID:
18251697
32.

Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.

Denoël PA, Goldblatt D, de Vleeschauwer I, Jacquet JM, Pichichero ME, Poolman JT.

Clin Vaccine Immunol. 2007 Oct;14(10):1362-9. Epub 2007 Aug 15.

33.

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

Weynants VE, Feron CM, Goraj KK, Bos MP, Denoël PA, Verlant VG, Tommassen J, Peak IR, Judd RC, Jennings MP, Poolman JT.

Infect Immun. 2007 Nov;75(11):5434-42. Epub 2007 Jul 30.

34.

Acellular pertussis vaccines and the role of pertactin and fimbriae.

Poolman JT, Hallander HO.

Expert Rev Vaccines. 2007 Feb;6(1):47-56. Review.

PMID:
17280478
35.
36.

Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB.

Pettersson A, Kortekaas J, Weynants VE, Voet P, Poolman JT, Bos MP, Tommassen J.

Vaccine. 2006 Apr 24;24(17):3545-57. Epub 2006 Feb 20.

PMID:
16517031
37.

Pneumococcal vaccine development.

Poolman JT.

Expert Rev Vaccines. 2004 Oct;3(5):597-604. Review.

PMID:
15485339
38.

Enhancement of vaccine-specific cellular immunity in infants by passively acquired maternal antibody.

Rowe J, Poolman JT, Macaubas C, Sly PD, Loh R, Holt PG.

Vaccine. 2004 Sep 28;22(29-30):3986-92.

PMID:
15364448
39.

Preparation of polysaccharide-conjugate vaccines.

Peeters CC, Lagerman PR, de Weers O, Oomen LA, Hoogerhout P, Beurret M, Poolman JT, Reddin KM.

Methods Mol Med. 2003;87:153-74. No abstract available.

PMID:
12958455
40.

Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA.

Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC.

Infect Immun. 2001 Oct;69(10):5997-6003.

41.

Heterogeneity in diphtheria-tetanus-acellular pertussis vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic th1 function.

Rowe J, Macaubas C, Monger T, Holt BJ, Harvey J, Poolman JT, Loh R, Sly PD, Holt PG.

J Infect Dis. 2001 Jul 1;184(1):80-8. Epub 2001 May 29.

PMID:
11398113
42.

Developing a nontypeable Haemophilus influenzae (NTHi) vaccine.

Poolman JT, Bakaletz L, Cripps A, Denoel PA, Forsgren A, Kyd J, Lobet Y.

Vaccine. 2000 Dec 8;19 Suppl 1:S108-15. Review.

PMID:
11163473
43.

Animal models for meningococcal disease.

Gorringe AR, Reddin KM, Voet P, Poolman JT.

Methods Mol Med. 2001;66:241-54. doi: 10.1385/1-59259-148-5:241.

PMID:
21336759
44.

Outer membrane protein vesicle vaccines for meningococcal disease.

Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E.

Methods Mol Med. 2001;66:81-107. doi: 10.1385/1-59259-148-5:81.

PMID:
21336749
45.

Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized.

Rowe J, Macaubas C, Monger TM, Holt BJ, Harvey J, Poolman JT, Sly PD, Holt PG.

Infect Immun. 2000 Jul;68(7):3873-7.

46.

The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis.

Jennings MP, Srikhanta YN, Moxon ER, Kramer M, Poolman JT, Kuipers B, van der Ley P.

Microbiology. 1999 Nov;145 ( Pt 11):3013-21.

PMID:
10589709
47.

Cardiovascular aspects of experimental meningococcal sepsis in young and older awake piglets: age-related differences.

Hazelzet JA, Stubenitsky R, Petrov AB, van Wieringen GW, van der Voort E, Hess J, Hop WC, Thijs LG, Duncker DJ, Poolman JT, Verdouw PD.

Shock. 1999 Aug;12(2):145-54.

PMID:
10446896
48.

Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice.

Peeters CC, Claassen IJ, Schuller M, Kersten GF, van der Voort EM, Poolman JT.

Vaccine. 1999 Jun 4;17(20-21):2702-12.

PMID:
10418921
49.

Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.

Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Høiby EA, Holst J, Nøkleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA.

JAMA. 1999 Apr 28;281(16):1520-7.

PMID:
10227322
50.

Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response.

Rodriguez ME, van den Dobbelsteen GP, Oomen LA, de Weers O, van Buren L, Beurret M, Poolman JT, Hoogerhout P.

Vaccine. 1998 Dec;16(20):1941-9.

PMID:
9796048

Supplemental Content

Loading ...
Support Center